Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer | Zendy

Christine Ribic | Zendy; Daniel J. Sargent | Zendy; Malcolm J. Moore | Zendy; Stephen N. Thibodeau | Zendy; Amy J. French | Zendy; Richard M. Goldberg | Zendy; Stanley R. Hamilton | Zendy; Pierre LaurentPuig | Zendy; Robert Gryfe | Zendy; Lois E. Shepherd | Zendy; Dongsheng Tu | Zendy; Mark Redston | Zendy; Steven Gallinger | Zendy

Open Access

Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

Author(s) -

Christine Ribic,

Daniel J. Sargent,

Malcolm J. Moore,

Stephen N. Thibodeau,

Amy J. French,

Richard M. Goldberg,

Stanley R. Hamilton,

Pierre LaurentPuig,

Robert Gryfe,

Lois E. Shepherd,

Dongsheng Tu,

Mark Redston,

Steven Gallinger

Publication year - 2003

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa022289

Subject(s) - microsatellite instability , hazard ratio , medicine , colorectal cancer , confidence interval , fluorouracil , oncology , microsatellite , cancer , adjuvant therapy , rectum , chemotherapy , gastroenterology , allele , biology , genetics , gene

Colon cancers with high-frequency microsatellite instability have clinical and pathological features that distinguish them from microsatellite-stable tumors. We investigated the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy with fluorouracil in stage II and stage III colon cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research